<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Xu</forename><surname>Qian</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Otolaryngology, Head and Neck Surgery</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Otolaryngology, Head and Neck Surgery</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Histology and Embryology</orgName>
								<orgName type="department" key="dep2">Zhejiang Provincial Key Laboratory of Medical Genetics</orgName>
								<orgName type="institution">Wenzhou medical University</orgName>
								<address>
									<settlement>Wenzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chenming</forename><surname>Ma</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Otolaryngology, Head and Neck Surgery</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Otolaryngology, Head and Neck Surgery</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><forename type="middle">K</forename><surname>Hoffmann</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Otolaryngology, Head and Neck Surgery</orgName>
								<orgName type="institution">University of Ulm</orgName>
								<address>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><forename type="middle">M</forename><surname>Kaufmann</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Clinic for Gynecology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Mitte and Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Andreas</forename><forename type="middle">E</forename><surname>Albers</surname></persName>
							<email>andreas.albers@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Otolaryngology, Head and Neck Surgery</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Otolaryngology, Head and Neck Surgery</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">2D3408168D9C8278DD8FC2ED3CB300FA</idno>
					<idno type="DOI">10.1186/s40064-015-0988-5</idno>
					<note type="submission">Received: 9 November 2014 Accepted: 17 April 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:40+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Head and neck carcinoma</term>
					<term>Induction chemotherapy</term>
					<term>Docetaxel</term>
					<term>Cisplatin</term>
					<term>Fluoruracil</term>
					<term>Survival</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: The objective of this study was to compare the efficacy and safety of taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) with cisplatin plus fluorouracil (PF) regimen by a meta-analysis of data retrieved from the literature.</s></p><p><s>Methods: Seven randomized clinical trials were identified, which included patients with advanced head and neck cancer who underwent induction chemotherapy with either a Tax-PF or PF protocol.</s><s>The outcomes included the 3-year and 5-year overall survival (OS) and progression-free survival (PFS), overall response rate (ORR) and different types of adverse events.</s><s>Results: The 3-year OS rate (HR: 1.14; 95% CI: 1.03 to 1.25; P = 0.008), 3-year PFS rate (HR: 1.24; 95% CI: 1.08 to 1.43; P = 0.002), 5-year OS rate (HR: 1.30; 95% CI, 1.09 to 1.55;P = 0.003), 5-year PFS rate (HR: 1.39; 95% CI, 1.14 to 1.70; P = 0.001) and ORR to chemotherapy (OR 1.66; 95% CI, 1.35 to 2.05; P &lt; 0.001) of the patients in the Tax-PF group were statistically superior to those in the PF group.</s><s>In terms of toxicities, the incidence of febrile neutropenia (OR 2.36; 95% CI, 1.62 to 3.46; P &lt; 0.001), alopecia (OR 8.22; 95% CI, 3.99 to 16.92; P &lt; 0.001), diarrhea (OR 1.57; 95% CI, 1.05 to 2.36; P = 0.03) and leukopenia (OR 2.79; 95% CI, 1.86 to 4.21; P &lt; 0.001) was higher in the Tax-PF group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion:</head><p><s>The Tax-PF induction chemotherapy improved PFS and OS, and the ORR was better as compared to PF-based therapy regimens at the cost of a higher incidence of adverse events.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Head and neck squamous cell carcinoma is one of commonest malignant tumors, frequently diagnosed in an unresectable advanced stage <ref type="bibr" target="#b24">(Siegel et al. 2014)</ref>.</s><s>A meta-analysis on chemotherapy in head and neck cancer (MACH-NC) has demonstrated that concomitant chemoradio-therapy using traditional cisplatin and fluorouracil (PF) regimen improved the survival in patients with distant metastases and should be regarded as the principal treatment <ref type="bibr" target="#b17">(Pignon et al. 2009</ref>).</s><s>Nevertheless, investigators are continuously evaluating new regimens in the induction setting to improve ORR, PFS and OS.</s><s>Among agents introduced in the 1990s, taxanes have shown great promise for the treatment of head and neck squamous cell carcinoma (HNSCC) <ref type="bibr" target="#b23">(Schrijvers and Vermorken 2000)</ref>.</s><s>The clinical efficacy of induction chemotherapy using a PF regimen doubled while a three-drug combination of taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) is still undergoing evaluation in several randomized controlled trials (RCTs) with varying results <ref type="bibr">(Blanchard et al. 2013;</ref><ref type="bibr" target="#b6">Forastiere et al. 2013;</ref><ref type="bibr" target="#b26">Tural and Kilickap 2014)</ref>.</s></p><p><s>This meta-analysis was conducted to review all eligible RCTs comparing combined therapy with or without taxanes, with the aim of investigating whether Tax-PF therapy is more efficient than PF therapy for advanced head and neck cancer while adverse effects are still tolerable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Literature search</head><p><s>PubMed, Embase, SpringerLink, MEDLINE, the Cochrane Library and the American Society of Clinical Oncology (ASCO) Annual Meeting and ASCO virtual meeting databases were searched for entries until June 2014, using the following search keywords: "randomized", "head and neck cancer", "HNSCC", "induction chemotherapy" and "taxanes or docetaxel or paclitaxel".</s><s>Articles and general reviews of this topic were examined and excluded manually.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study selection</head><p><s>Clinical trials that fulfilled the following criteria were included in the study: (1) prospective RCT; (2) original articles that include a censored number of patients or Kaplan-Meier-curves; (3) studies that analyzed combined therapy regimen with taxanes versus without taxanes; (4) comparisons of combined Tax-PF induction chemotherapy to regimen with traditional PF double-chemotherapy (Figure <ref type="figure" target="#fig_0">1</ref>).</s></p><p><s>To limit publication bias, only published data were included.</s><s>Studies containing one of the following criteria (1) phase I clinical trial; (2) retrospective trial; (3) any review, comment, and case report were excluded from the analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data extraction and study quality</head><p><s>Studies were extracted from the databases by two of the authors separately.</s><s>Next, between the authors a consensus was achieved that the data from the chosen publications met the inclusion criteria.</s><s>Then the following information were extracted from each study, however some articles did not contain all of the following information: first author, publication year, country of patient's origin, treatment regimen, patient number, age, gender, treatment line, ECOG (Eastern Cooperative Oncology Group) performance status (PS) or WHO status or Karnofsky status (KPS), median overall survival (OS), progression-free survival (PFS), overall response rate (ORR), adverse events (AEs), specific grade 3-4 toxicity data and general symptoms (alopecia, infection, and asthenia), hematological system syndrome (neutropenia, thrombocytopenia, and anemia), digestive system syndrome (nausea/vomiting, diarrhea, and anorexia), and neuropathy.</s><s>In studies where the log hazard ratio (HR) and its variance was not explicitly presented the method described by Parmar et al. was applied to extract estimates of these statistics <ref type="bibr" target="#b15">(Parmar et al. 1998</ref>).</s><s>In those instances where studies contained overlapping sets of patients, the longest follow-up or the largest number of events was selected.</s><s>The methodological quality of the reports integrated in this meta-analysis was evaluated using the Jadad composite scale <ref type="bibr" target="#b10">(Jadad et al. 1996;</ref><ref type="bibr" target="#b14">Moher et al. 1998)</ref>.</s><s>A general quality score was applied to each study as follows: 0 (non-randomized controlled trials), 1, 2 (low quality studies), 3, 5 (high quality studies).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>The outcomes relevant for this meta-analysis were PFS, OS, ORR and toxicity.</s><s>PFS was defined by the period from random assignment to the first documented disease progression.</s><s>OS was defined by the period from random assignment to death from any cause, censoring patients who had not died at the date last known alive.</s><s>ORR was defined as the sum of partial and complete response rates (according to the Response Evaluation Criteria in Solid Tumors (RECIST) <ref type="bibr" target="#b25">(Therasse et al. 2000)</ref>.</s><s>Toxicity was graded according to the Common Toxicity Criteria version 2 (http://ctep.cancer.gov).</s><s>The overall HRs for OS and PFS, the odds ratios (ORs) for ORR and AEs were calculated using statistical software (Stata version 13.0).</s><s>Efficacy analysis was based on the intent-to-treat population, which was defined as all randomly assigned patients.</s><s>All patients who received at least one dose of the study drug were included in safety analysis.</s><s>A p-value less than 0.05 was considered significant.</s><s>An HR &gt; 1 reflects a favorable outcome in the Tax-PF arm for response rate while an OR &gt; 1 indicates better overall response rates or higher toxicity in the Tax-PF arm.</s><s>Both the fixed-effects model and the random-effects model was used to calculate the pooled estimates of efficacy.</s><s>The quantification of the heterogeneity was calculated by the Cochrane Q statistic and the I 2 value.</s><s>The assumption of homogeneity was deemed invalid, when a p-value was &lt; 0.1.</s><s>Then the random-effects models were used after exploring the causes of heterogeneity.</s><s>Otherwise, the fixed-effects models were used.</s><s>The results of this meta-analysis were presented by forest plots.</s><s>The individual squares represent each study's HR or OR estimate while the lines extending from the squares represent the 95% confidence interval (CI) for the estimate.</s><s>The size of the square represents the weight that the corresponding study exerts in the meta-analysis.</s><s>In addition, the funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR) and Begg's and the Egger's linear regression test were used to estimate the publication bias.</s><s>The significance of the intercept was displayed using the t-test suggested by Begg (p &lt; 0.05 was considered as statistically significant) <ref type="bibr" target="#b4">(Egger et al. 1997</ref>) (see Additional file 1: Figure <ref type="figure" target="#fig_0">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Description of included trials</head><p><s>A total of 1098 potentially relevant papers or abstracts were initially retrieved from the databases, of which 1091 could be excluded after thorough screening.</s><s>A flow chart summarizing search results and exclusion strategy is provided in Figure <ref type="figure" target="#fig_0">1</ref>.</s><s>Finally, seven clinical trials were selected for the meta-analysis <ref type="bibr" target="#b7">(Hitt et al. 2005;</ref><ref type="bibr" target="#b19">Posner et al. 2007;</ref><ref type="bibr" target="#b27">Vermorken et al. 2007;</ref><ref type="bibr" target="#b18">Pointreau et al. 2009;</ref><ref type="bibr" target="#b28">Vermorken et al. 2011;</ref><ref type="bibr" target="#b11">Lorch et al. 2011;</ref><ref type="bibr" target="#b8">Hitt et al. 2014)</ref>.The main characteristics and detailed induction chemotherapy regimens are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Three-year efficacy rate</head><p><s>Four trials <ref type="bibr" target="#b19">(Posner et al. 2007;</ref><ref type="bibr" target="#b27">Vermorken et al. 2007;</ref><ref type="bibr" target="#b18">Pointreau et al. 2009;</ref><ref type="bibr" target="#b8">Hitt et al. 2014</ref>) provided data regarding the 3-year PFS rate.</s><s>When combined, the data from the four trials yielded an estimated common HR of 1.24 (95% CI: 1.08 to 1.43).</s><s>A significantly positive effect on survival was found for the use of Tax-PF for induction chemotherapy (P =0.002).</s><s>Five trials <ref type="bibr" target="#b7">(Hitt et al. 2005;</ref><ref type="bibr" target="#b19">Posner et al. 2007;</ref><ref type="bibr" target="#b27">Vermorken et al. 2007;</ref><ref type="bibr" target="#b18">Pointreau et al. 2009;</ref><ref type="bibr" target="#b8">Hitt et al. 2014</ref>) provided data on the 3-year OR rate.</s><s>Patients treated with the Tax-PF regimen had a significantly longer 3-year OR rate (HR: 1.14; 95% CI: 1.03 to 1.25; P = 0.008).</s><s>However, a between-trial-heterogeneity was observed for the OS analysis with an I 2 value of 57.2% (P = 0.053), but not in PFS (P = 0.545).</s><s>This heterogeneity was mainly related to the Spanish Head and Neck Cancer Cooperative Group (TTCC) in 2014 <ref type="bibr" target="#b8">(Hitt et al. 2014</ref>).</s><s>After eliminating this study, a reduction in the hazard of progression for Tax-PF group (HR 1.19, 95% CI 1.07 to 1.32, heterogeneity P = 0.132, I 2 = 46.5%)</s><s>was found.</s><s>The main study results are detailed in Figure <ref type="figure" target="#fig_1">2</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Five-year efficacy rate</head><p><s>Of the four eligible studies, 2 trials <ref type="bibr" target="#b28">(Vermorken et al. 2011;</ref><ref type="bibr" target="#b11">Lorch et al. 2011</ref>) were a long-term update to previous trials.</s><s>From these studies, we could extract data to calculate the five-year efficacy rate for this meta-analysis.</s><s>Tax-PF induction chemotherapy improved the PFS rate when compared with PF induction chemotherapy, with an HR of death of 1.39 (95% CI, 1.14 to 1.70; P = 0.001; Figure <ref type="figure" target="#fig_1">2</ref>).</s><s>Tax-PF induction chemotherapy also improved the OS rate, with an HR of 1.30 (95% CI, 1.09 to 1.55; P = 0.003).</s><s>The test for heterogeneity of the data yielded a p-value &gt; 0.1 (PFS: 0.387 and OS: 0.429); thus, we accepted the hypothesis of homogeneity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overall response rate</head><p><s>The data of five trials <ref type="bibr" target="#b7">(Hitt et al. 2005;</ref><ref type="bibr" target="#b19">Posner et al. 2007;</ref><ref type="bibr" target="#b27">Vermorken et al. 2007;</ref><ref type="bibr" target="#b18">Pointreau et al. 2009;</ref><ref type="bibr" target="#b8">Hitt et al. 2014)</ref> were included to determine the overall response (WHO criteria) to chemotherapy.</s><s>Patients treated with Tax-PF had a significantly higher ORR (OR 1.66; 95% CI, 1.35 to 2.05; P &lt; 0.001).</s><s>No significant heterogeneity was found among studies used for analysis (heterogeneity P = 0.162, I 2 = 38.8%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxicity</head><p><s>Data to analyse adverse events could be extracted from seven trials.</s><s>The results are presented in Figure <ref type="figure" target="#fig_2">3</ref>.</s></p><p><s>Patients treated with the Tax-PF regimen had a significantly higher occurrence of grade 3 to 4 febrile neutropenia (OR 2.36; 95% CI, 1.62 to 3.46; P &lt; 0.001), alopecia (OR 8.22; 95% CI, 3.99 to 16.92; P &lt; 0.001), diarrhea (OR 1.57; 95% CI, 1.05 to 2.36; P = 0.03) and leukopenia (OR 2.79; 95% CI, 1.86 to 4.21; P &lt; 0.001).</s><s>Heterogeneity was found for some adverse events, which may be attributed to patient characteristics and to the use of different agents at various dosages in the studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publication bias</head><p><s>Egger's test was performed to determine the publication bias of the literature.</s><s>The results of Egger's test did not suggest any evidence of publication bias (P = 0.854) (see Additional file 1: Figure <ref type="figure" target="#fig_0">S1</ref>).</s><s>Taxanes are a group of anticancer drugs that function by disruption of microtubule assembly and -function and can effectively block the cell cycle in G2/M phase which results in a mitotic arrest <ref type="bibr" target="#b23">(Schrijvers and Vermorken 2000)</ref>.</s><s>In vitro studies suggested that taxanes also may play a role in radiation sensitization <ref type="bibr" target="#b3">(Cui et al. 2014</ref>).</s><s>Since the 1990s, taxanes have been evaluated for their potential to treat HNSCC <ref type="bibr" target="#b22">(Qin et al. 2012)</ref>.</s></p><p><s>The MACH-NC Collaborative Group performed an individual patient data meta-analysis with an inclusion of 1772 patients that were recruited between 1998 and 2007.</s><s>Patients treated with Tax-PF had the benefit of a higher rate of loco-regional control (HR, 0.79; 95% CI, 0.66-0.97;</s><s>P = 0.007), suffered from distant failures less frequently (HR, 0.63; 95% CI, 0.45-0.89;</s><s>p = 0.009) and showed an absolute decrease in mortality at 5 years of 9.3% (PF vs TPF: 60.1% vs 50.8%).</s><s>Nevertheless, the trials displayed heterogeneity regarding criteria such as patient inclusion, patient characteristics, drug regimens, tumor site, treatment intent, primary endpoint, and especially, definitive local treatment <ref type="bibr" target="#b6">(Forastiere et al. 2013)</ref>.</s><s>The individual trial results also diminished the importance of the meta-analysis <ref type="bibr" target="#b12">(Mak and Glisson 2014)</ref>.</s><s>The outcome of induction chemotherapy with a three-drugcombination consisting Tax-PF for locally advanced head and neck cancer is still a subject of debate and will remain so for the near future.</s></p><p><s>This meta-analysis evaluated not only the 3-year efficacy and safety, but also demonstrated for the first time a significant improvement in 5-year efficacy and safety of Tax-PF from two clinical studies.</s><s>The long-term results from the other three trials <ref type="bibr" target="#b8">(Hitt et al. 2014;</ref><ref type="bibr" target="#b7">Hitt et al. 2005;</ref><ref type="bibr" target="#b18">Pointreau et al. 2009)</ref> are not available at present.</s><s>Therefore, we conclude at this point in time that the induction chemotherapy regimen using Tax-PF is superior to the PF regimen in terms of efficacy according to the currently available data.</s><s>However, the long-term results of the currently ongoing trials should be included whenever available to increase the validity of this statement.</s></p><p><s>With regards to toxicities, the Tax-PF regimen led to a higher rate of grade 3 to 4 febrile neutropenia, alopecia, diarrhea and leucopenia as it has been shown in this meta-analysis (Figure <ref type="figure" target="#fig_2">3</ref>).</s><s>No difference was seen in toxicity-related mortality, implying that there was no increase in treatment-related deaths with Tax-PF treatment as compared with PF-regimen alone.</s><s>The incidences of lethargy, infection, nausea and vomiting, peripheral neuropathy, renal function and anemia were not significantly different.</s></p><p><s>Severe adverse effects seemed predictable and manageable.</s><s>Taking into account the toxicity-profile of Tax-PFinduction chemotherapy on one hand and the improved PFS and OS on the other future studies should aim to identify characteristics of treated patients that will help to determine the risk and benefit of distinct groups.</s><s>One currently proposed strategy is a stratification of trial-results based on the distinct etiologies of HNSCC in future research since human papillomavirus (HPV)-and tobaccorelated HNSCC exist <ref type="bibr" target="#b21">(Qian et al. 2014;</ref><ref type="bibr" target="#b20">Qian et al. 2013</ref>).</s><s><ref type="bibr">Fakhry et al. observed</ref> the HPV status of oropharyngeal HNSCC in a prospective clinical trial and confirmed, that tumor HPV status is strongly associated with therapeutic response and survival <ref type="bibr" target="#b5">(Fakhry et al. 2008)</ref>.</s><s>Patients with HPV-positive tumors displayed higher response rates to induction chemotherapy including intravenous paclitaxel (82% vs 55%, P = 0.01) and after chemoradiation treatment (84% vs 57%, P = 0.007) than those with HPV-negative tumors.</s><s>After a median follow-up of 39.1 months, compared with patients with HPV-negative tumors, patients with HPV-positive tumors demonstrated a significant improved OS (2-year OS = 95% vs 62%, difference = 33%, 95% CI = 18.6% to 47.4%, P = 0.005, log-rank test).</s><s>Consequently, de-escalation treatment protocols of HPV-associated HNSCC were developed <ref type="bibr" target="#b13">(Masterson et al. 2014</ref>).</s><s>However, it will be necessary and of clinical interest to identify further the underlying mechanisms that determine a response to induction chemotherapy in patients with HPV-associated HNSCC and non-HPV-associated HNSCC to facilitate a proper selection of patients that are most likely to benefit from this therapy and thereby justifying the relatively high risk of therapy-induced toxicity.</s><s>These approaches may include reverse bedside-to-bench research to stratify the influence of patient' habits and biological factors on therapeutic outcome.</s></p><p><s>As stated by Forastiere et al. and others the ideal sequence of chemotherapy, radiation, and surgery for the management of loco-regionally advanced HNSCC has not been finally defined yet <ref type="bibr" target="#b6">(Forastiere et al. 2013;</ref><ref type="bibr" target="#b0">Argiris et al. 2008)</ref>.</s></p><p><s>Although non-surgical standard treatment of locally advanced HNSCC is concurrent chemoradio-therapy <ref type="bibr" target="#b17">(Pignon et al. 2009;</ref><ref type="bibr" target="#b16">Petrelli et al. 2014;</ref><ref type="bibr" target="#b13">Masterson et al. 2014)</ref>, there is emerging evidence, being now further consolidated and explored, that treatment with a threedrug regimen such as Tax-PF followed by surgery and consolidation chemoradio-therapy of patients with recurrent advanced HNSCC improved the response rates and survival <ref type="bibr" target="#b30">(Yang et al. 2014)</ref>.</s><s>Other groups also reported that induction chemotherapy tended to improve clinical outcome with manageable toxicity <ref type="bibr" target="#b29">(Won et al. 2014)</ref>.</s><s>Also the choice of the chemotherapeutic agent in a noninduction setting is not without controversy.</s><s>While some authors view platinum-based chemoradio-therapy as the treatment of choice for locally advanced HNSCC <ref type="bibr" target="#b16">(Petrelli et al. 2014;</ref><ref type="bibr" target="#b13">Masterson et al. 2014</ref>) and superior to radiotherapy combined with cetuximab, which should therefore be for cases where the application of platinum-based agents is contraindicated, others recently argued that an improved OS and reduced toxicity supports the choice of taxane-based regimens in a concurrent setting over platinum non-taxane containing regimen <ref type="bibr" target="#b1">(Behera et al. 2014</ref>).</s><s>However, the findings also indicated that a better standardization of a taxane-based regimen is needed <ref type="bibr" target="#b1">(Behera et al. 2014)</ref>.</s></p><p><s>Some shortcomings of this analysis should be taken into account: First, like every meta-analysis, the quality of the results is limited by the quality of the included trials.</s><s>Second, treatments were involved in a few trials based on the different dosages.</s><s>Third, only seven RCTs were included and not all articles contained data of OS, PFS, ORR, and some adverse effects.</s><s>Fourth, although publication bias was not found, the influence of the omission of further ongoing or yet unpublished studies cannot be included at the time of the preparation of this manuscript.</s><s>However more long-term evidence from randomized studies is needed to further validate the therapeutic efficacy of Tax-PF.</s><s>Finally, heterogeneity of the data exists in some outcomes in this meta-analysis, for which differences in patient populations, concurrent chemoradio-therapies, lengths of treatment and tumor performance status across the included trials may be responsible.</s></p><p><s>In conclusion, our data demonstrate that the Tax-PF induction chemotherapy regimens lead to a significant survival advantage at the cost of an increased rate of toxicity-related adverse effects as compared to the PF regimen.</s><s>Therefore, before administration of Tax-PF induction chemotherapy regimen, followed by radiotherapy or concurrent chemoradio-therapy, a careful selection of patients seems advisable to reduce the incidence and severity of adverse effects.</s><s>Ideally, these patients should be included in clinical trials to provide more data for future analysis and perspectively for better clinical decision making.</s><s>For future research, investigators should include markers in their studies that help to distinguish subsets of patients e.g. according to risk-profile and HPV association of the HNSCC to further characterize groups at high risk for adverse effects and those most likely to benefit.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure1Flow-chart for identification of eligible studies.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Clinical outcome after three 3 and 5 years.</s></p></div></figDesc><graphic coords="5,127.28,96.27,340.76,78.58" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Toxicity profile of Tax-PF and PF regimen.</s></p></div></figDesc><graphic coords="5,127.28,456.10,340.76,258.41" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Characteristics of randomized controlled clinical trials in the meta-analysis</s></p></div></figDesc><table><row><cell>First</cell><cell>Year Study</cell><cell cols="3">NCT number Center Inclusion</cell><cell>Total</cell><cell>TPF/</cell><cell>Follow-up</cell><cell>Induction</cell><cell>Treatment</cell><cell>Performance</cell><cell>Median</cell><cell>Male</cell><cell>Unresectable</cell><cell>Jaded</cell></row><row><cell>author</cell><cell></cell><cell></cell><cell></cell><cell>period</cell><cell>number</cell><cell>PF</cell><cell>mean</cell><cell>Chemotherapy (IC)</cell><cell>after IC</cell><cell>status</cell><cell>age(year)</cell><cell>(%)</cell><cell>(%)</cell><cell>score</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(month)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hitt</cell><cell>2005 /</cell><cell>/</cell><cell>SP</cell><cell>1998-</cell><cell>382</cell><cell>189/</cell><cell>23.2</cell><cell>paclitaxel+PF</cell><cell cols="2">chemoradiotherapy ECOG 0-1</cell><cell>TPF 56/PF</cell><cell>TPF 94/</cell><cell>TPF 64/PF 66 4</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>2001</cell><cell></cell><cell>193</cell><cell></cell><cell>vs PF</cell><cell></cell><cell></cell><cell>55</cell><cell>PF 94</cell></row><row><cell>Hitt</cell><cell>2014 TTCC</cell><cell cols="2">NCT00261703 SP</cell><cell>2002-</cell><cell>439</cell><cell>155/</cell><cell cols="2">23.8/22.1 docetaxel+PF</cell><cell cols="2">chemoradiotherapy ECOG 0-1</cell><cell>TPF 58/PF</cell><cell>TPF 94/</cell><cell>100</cell><cell>4</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>2007</cell><cell></cell><cell>156</cell><cell></cell><cell>vs PF</cell><cell></cell><cell></cell><cell>58</cell><cell>PF 93</cell></row><row><cell>Lorch</cell><cell cols="3">2011 TAX324 NCT00273546 US</cell><cell>1999-</cell><cell>501</cell><cell>255/</cell><cell>72.2</cell><cell>docetaxel+PF</cell><cell cols="2">chemoradiotherapy WHO-PS 0-1</cell><cell>TPF 55/PF</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>2003</cell><cell></cell><cell>246</cell><cell></cell><cell>vs PF</cell><cell></cell><cell></cell><cell>56</cell><cell></cell></row><row><cell>Posner</cell><cell cols="3">2007 TAX324 NCT00273546 US</cell><cell>1999-</cell><cell>501</cell><cell>255/</cell><cell>42</cell><cell>docetaxel+PF</cell><cell cols="2">chemoradiotherapy WHO-PS 0-1</cell><cell>TPF 55/PF</cell><cell>TPF 84/</cell><cell>TPF 67/</cell><cell>4</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>2003</cell><cell></cell><cell>246</cell><cell></cell><cell>vs PF</cell><cell></cell><cell></cell><cell>56</cell><cell>PF 83</cell><cell>PF 64</cell></row><row><cell cols="2">Vermorken 2007 EORTC</cell><cell cols="2">NCT00003888 BL</cell><cell>1999-</cell><cell>358</cell><cell>177/</cell><cell>32.5</cell><cell>docetaxel+PF</cell><cell>radiotherapy</cell><cell>WHO-PS 0-1</cell><cell>TPF 53/PF</cell><cell>TPF 90/</cell><cell>100</cell><cell>4</cell></row><row><cell></cell><cell>24971/</cell><cell></cell><cell></cell><cell>2002</cell><cell></cell><cell>181</cell><cell></cell><cell>vs PF</cell><cell></cell><cell></cell><cell>53</cell><cell>PF 90</cell></row><row><cell></cell><cell>TAX323</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Vermorken 2011 EORTC</cell><cell cols="2">NCT00003888 BL</cell><cell>/</cell><cell>308</cell><cell>156/</cell><cell>103.2</cell><cell>docetaxel+PF</cell><cell>radiotherapy</cell><cell>/</cell><cell>/</cell><cell>/</cell><cell>100</cell><cell>3</cell></row><row><cell></cell><cell>24971/</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>152</cell><cell></cell><cell>vs PF</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>TAX323</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">Pointreau 2009 GORTEC NCT00169182 FR</cell><cell>2000-</cell><cell>213</cell><cell>110/</cell><cell>36</cell><cell>docetaxel+PF</cell><cell>radiotherapy and/or</cell><cell>Karnofsky</cell><cell>TPF</cell><cell>TPF 92/</cell><cell>/</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>2005</cell><cell></cell><cell>103</cell><cell></cell><cell>vs PF</cell><cell>chemoradiotherapy</cell><cell>PS 100-80</cell><cell>57/PF 56</cell><cell>PF 94</cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional file</head><p><s>Additional file 1: Figure <ref type="figure">S1</ref>.</s><s>Publication bias.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>The authors declare that they have no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contribution</head><p><s>XQ and CM performed the database searches.</s><s>XQ, CM and AEA analyzed the data.</s><s>XQ, CM, AEA, AMK and TK prepared the manuscript.</s><s>All authors read and approved the final manuscript.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Head and neck cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Argiris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Karamouzis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Ferris</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(08)60728-X</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="issue">9625</biblScope>
			<biblScope unit="page" from="1695" to="1709" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review</title>
		<author>
			<persName><forename type="first">M</forename><surname>Behera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Owonikoko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Ramalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Khuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Beitler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Saba</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.oraloncology.2014.06.014</idno>
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="888" to="894" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Meta-Analysis of Chemotherapy in H, Neck Cancer IPCG (2013) Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group</title>
		<author>
			<persName><forename type="first">P</forename><surname>Blanchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bourhis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lacas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Posner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Vermorken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bourredjem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Calais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Paccagnella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pignon</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2012.47.7802</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2854" to="2860" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Enhancement of radiotherapy efficacy by docetaxel-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Yue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">X</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">P</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.canlet.2013.12.002</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="53" to="62" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Bias in meta-analysis detected by a simple, graphical test</title>
		<author>
			<persName><forename type="first">M</forename><surname>Egger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Davey</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Minder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="issue">7109</biblScope>
			<biblScope unit="page" from="629" to="634" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fakhry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Westra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cmelak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Ridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pinto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Forastiere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Gillison</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djn011</idno>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="261" to="269" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Induction chemotherapy meta-analysis in head and neck cancer: right answer, wrong question</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Forastiere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Adelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Manola</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2013.50.3136</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2844" to="2846" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Pousa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martinez-Trufero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Escrig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Carles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rizo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Isla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Vega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Marti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lobo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pastor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Valenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Belon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chaib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pallares</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2004.00.1990</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">34</biblScope>
			<biblScope unit="page" from="8636" to="8645" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Pousa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berrocal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garcia-Giron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Irigoyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sastre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martinez-Trufero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Brandariz</forename><surname>Castelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Verger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cruz-Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<pubPlace>Spanish H, Neck Cancer Cooperative G</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title/>
		<idno type="DOI">10.1093/annonc/mdt461</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="216" to="225" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Assessing the quality of reports of randomized clinical trials: is blinding necessary?</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Jadad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Carroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jenkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Gavaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Mcquay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Control Clin Trials</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lorch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Goloubeva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Haddad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sarlis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tishler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fasciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Sammartino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Posner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Taxs</forename><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(10)70279-5</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="153" to="159" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Is there still a role for induction chemotherapy in locally advanced head and neck cancer?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Glisson</surname></persName>
		</author>
		<idno type="DOI">10.1097/CCO.0000000000000073</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="247" to="251" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials</title>
		<author>
			<persName><forename type="first">L</forename><surname>Masterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Moualed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">W</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Dwivedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Tysome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Benson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Sterling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sudhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Goon</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejca.2014.07.001</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="2636" to="2648" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</title>
		<author>
			<persName><forename type="first">D</forename><surname>Pham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Jadad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Moher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tugwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Klassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(98)01085-X</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="issue">9128</biblScope>
			<biblScope unit="page" from="609" to="613" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Parmar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Torri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Stewart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="2815" to="2834" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies</title>
		<author>
			<persName><forename type="first">F</forename><surname>Petrelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Coinu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Riboldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Borgonovo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ghilardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cabiddu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lonati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sarti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Barni</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.oraloncology.2014.08.005</idno>
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1041" to="1048" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pignon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Le Maitre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Maillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bourhis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M-Nc</forename><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.radonc.2009.04.014</idno>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="4" to="14" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Pointreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Garaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chapet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tuchais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tortochaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Faivre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Guerrif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alfonsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Calais</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djp007</idno>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="498" to="506" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Posner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Hershock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Blajman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mickiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Winquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gorbounova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tjulandin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Ervin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Raez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Spaulding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Tishler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Viroglio</forename><surname>Rdel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Venkatesan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Romanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Agarwala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Dugan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cmelak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Markoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Read</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Steinbrenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Colevas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Norris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Haddad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Taxs</forename><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa070956</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="1705" to="1715" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">ALDH1-positive cancer stem-like cells are enriched in nodal metastases of oropharyngeal squamous cell carcinoma independent of HPV status</title>
		<author>
			<persName><forename type="first">X</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Klussmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Kaufmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Albers</surname></persName>
		</author>
		<idno type="DOI">10.3892/or.2013.2340</idno>
	</analytic>
	<monogr>
		<title level="j">Oncol Rep</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1777" to="1784" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Prognostic significance of ALDH1A1-positive cancer stem cells in patients with locally advanced, metastasized head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">X</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Coordes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gekeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Klussmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Kaufmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Albers</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00432-014-1685-4</idno>
	</analytic>
	<monogr>
		<title level="j">J Cancer Res Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1151" to="1158" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Q</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Lei</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0051526</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">e51526</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Role of taxoids in head and neck cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Schrijvers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Vermorken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="199" to="208" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Cancer statistics</title>
		<author>
			<persName><forename type="first">R</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
		<idno type="DOI">10.3322/caac.21208</idno>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="9" to="29" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States</title>
		<author>
			<persName><forename type="first">P</forename><surname>Therasse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Arbuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Eisenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rubinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Verweij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Glabbeke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Van Oosterom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Christian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Gwyther</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="205" to="216" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Is taxane-cisplatin-fluorouracil superior to cisplatin-fluorouracil as induction chemotherapy in outcome in locally advanced head and neck cancers?</title>
		<author>
			<persName><forename type="first">D</forename><surname>Tural</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kilickap</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2013.52.5592</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">259</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Vermorken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Remenar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Van Herpen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gorlia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mesia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Degardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jelic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Betka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Preiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Den Weyngaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Awada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cupissol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Kienzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Desaunois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bernier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Lefebvre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ets</forename><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa071028</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="1695" to="1704" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Long-term results from EORTC24971/TAX323: comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Vermorken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Remenar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Van Herpen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Degardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Karra</forename><surname>Gurunath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fortpied</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>abstract</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Clinical outcome of induction chemotherapy in locally advanced head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Won</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Jeon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Le Yoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="5709" to="5714" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="3765" to="3773" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
